Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma

Hepatology

Liver decompensation in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab: a real-life study

Clin Gastroenterol Hepatol

Stella L, Pallozzi M, Cerrito L, Santopaolo F, Tovoli F, Hollande C, Sidali S, Stefanini B, Campani C, Pellegrini E, Cabibbo G, Marra F, Piscaglia F, Gasbarrini A, Pompili M, Bouattour M, Ponziani FR

doi: 10.1016/j.cgh.2024.12.028

Hepatology

Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study

Hepatology

Tovoli F, Iavarone M, Cabibbo G, Marra F, Vivaldi C, Dalbeni A, Ponziani FR, Palloni A, Bergamo F, Rimassa L, Lani L, Federico P, Svegliati-Baroni G, Ielasi L, Mazzarelli C, De Lorenzo S, Sacco R, Bruccoleri M, Celsa C, Mastro A, Masi G, Auriemma A, Stella L, Toniutto P, Villani R, Lonardi S, Pressiani T, Piscaglia F, ARTE study group

doi: 10.1097/HEP.0000000000001725

Gastrointestinal Cancer

Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration

J Hepatol

Lin YJ, Ou DL, Su YY, Hsu CL, Hsiao CF, Ko BS, Chen SC, Wang HW, Wang JH, Wu YM, Jeng YM, Lee WC, Chou SC, Chen TW, Chiu CF, Shiuan Lin Jr, Hsieh CH, Lee CC, Shen YS, Cheng AL, Chen LT, Hsu C

doi: 10.1016/j.jhep.2025.08.035

Gastrointestinal CancerHepatology

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Lai JC, Yang B, Lee HW, Lin H, Tsochatzis EA, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Duràn R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castera L, Lai M, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gómez M, Kim SU, Wong VW, Yip TC

doi: 10.1136/gutjnl-2025-334981

HepatitisHepatology

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Chang YP, Chen YC, Cheng PN, Fang YJ, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Lee FJ, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH, Liu CH

doi: 10.1136/gutjnl-2025-337275

Gastrointestinal Cancer

Traditional serrated adenomas associated with risk of subsequent high-risk polyps and colorectal cancer

Am J Gastroenterol

Chen Y, Polychronidis G, Zhang Y, Shen J, Lu Y, Du M, Song M

doi: 10.14309/ajg.0000000000003588

Colonoscopy

Individuals with polyps ≥10mm without other high-risk features have a similarly low post-colonoscopy colorectal cancer risk as those with no polyps

Endoscopy

van Roermund NS, van Leerdam ME, Spaander MCW, Dekker E, IJspeert JEG

doi: 10.1055/a-2730-6060

HepatitisHepatology

Validation of THCC-RI in the Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study

Clin Gastroenterol Hepatol

Kanwal F, Lopez C, Ning J, Luster M, Reddy KR, Parikh ND, Singal AG, Marrero JA, Chhatwal J, Feng Z, Page-Lester S, Koay EJ, El-Serag HB

doi: 10.1016/j.cgh.2026.01.041

Hepatology

High inherited risk predicts age-associated increases in fibrosis in patients with MASLD

J Hepatol

Díaz LA, Alazawi W, Agrawal S, Arab JP, Arrese M, Idalsoaga F, Barreyro FJ, Gadano A, Marciano S, Morales JM, Villela-Nogueira C, Leite N, Couto CA, Theodoro R, Joyner de Sousa Dias Monteiro M, Oliveira CP, Pessoa MG, Alvares-da-Silva MR, Madamba E, Bettencourt R, Richards LM, Majithia AR, Khera AV, Loomba R, Ajmera V

doi: 10.1016/j.jhep.2025.04.035

Related content

Liver decompensation in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab: a real-life study

Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study

Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Traditional serrated adenomas associated with risk of subsequent high-risk polyps and colorectal cancer

Individuals with polyps ≥10mm without other high-risk features have a similarly low post-colonoscopy colorectal cancer risk as those with no polyps

Validation of THCC-RI in the Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study

High inherited risk predicts age-associated increases in fibrosis in patients with MASLD